

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

For the month of February 2016

Commission File Number: 001-36581

**Vascular Biogenics Ltd.**

(Translation of registrant's name into English)

6 Jonathan Netanyahu St.  
Or Yehuda  
Israel 60376

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

## CONTENTS

On January 31, 2016, Professor Jacob George notified Vascular Biogenics Ltd. (the “Company”) of his resignation from the role of the Company’s Chief Scientific Officer, effective immediately, for personal reasons which are unrelated to the Company, its operations, policies or practices.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**VASCULAR BIOGENICS LTD.**

Date: February 1, 2016

By: /s/ Dror Harats

Name: Dror Harats

Title: Chief Executive Officer